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Summary: The Carcinoembryonic antigen (CEA) is a glycoprotein which is defined mainly by its immunochemical
properties. Essential biochemical properties of CEA are: its molecular weight of 180000—200000, the alkali stable
bond of the oligosaccharide unit to the peptide (GlcNAc-Asn), and the solubility in 0.6—1.0 mol/1 perchloric acid.
Most of the immunochemical and biochemical properties of CEA relate to preparations from liver metastases of
colonic carcinomas. Biochemical heterogeneity of CEA preparations can be shown by several biochemical procedures
e.g. isoelectric focussing, ion exchange chromatography and lectin affinity chromatography. CEA preparations that
show differences with respect to biochemical parameters, but behave idenfically when immunochemical methods are
applied, are called 'isomeric species' or 'isoantigens'.
Substaiices which react with anti-CEA sera but do not fulfill the criteria given for CEA are called 'CEA-related anti-
gens'. The CEA-related antigens can be further subclassified into the cross reacting antigens, the membrane variant
of CEA (CEA-M), and more or less well defined CEA related antigens which were isolated from sources different
from colonic carcinoma or its liver metastases.
It is still cqntroversial whether CEA is mainly a membrane glycoprotein or a secretory glycoprotein. The finding
that additional antigenic determinants are present on a membrane variant of CEA suggests that a CEA precursor or
a distinct CEA membrane variant may exist. CEA^M is only pärtially soluble in 0.6—0.9 mol/1 perchloric acid.
Many findings indicate that membrane glycoproteins from normal and tumour cells are glycosylated differently.
It has been suggested that glycosylation of CEA and CEA related antigens may be organ or phase specific. As per-
chloric acid extractipn is a generally used step in the Isolation procedure of CEA, variants of CEA with a low per-
chloric acid solubility due to incomplete glycosylation may escape the Isolation (e.g. CEA-M).
Recent results on the Isolation of CEA variants from sources other thän liver metastases of colonic carcinomas are
contradictory. CEA-reläted antigens shpwing ä close similarity to CEA, äs well äs CEA variants exhibiting consider-
able differences with respect to moleeülär weight and perchlorie acid solubility have been described.
Biochemische und immunchemische Aspekte des carcinoembryonalen Antigens (CEA) und CEA-ähnlicher Antigene:
Gegenwärtiger Stand und zukünftige Perspektiven
Zusammenfassung: Das carcinoembryonale Antigen (CEA) ist ein Glycoprotein, welches hauptsächlich durch seine
immunchemischen Eigenschaften definiert ist. Charakteristische biochemische Eigenschaften von CEA sind das Mole-
kulargewicht von 180000-200000, die alkalistabile Bindung der Oligpsaccharid-Seitenketten an die Peptidkette
•(GlcNAc-Asn) sowie die Löslichkeit in 0,6-1,0 mol/1 Perchlorsäure. Die immunchemischen und biochemischen
Eigenschaften von CEA beziehen sich im allgemeinen auf Präparatiöften von Lebermetastasen primärer Colon-
carcinome. CEAJPräparatipnen verhalten sich in Bezug auf verschiedene biochemische Kenngrößen heterogen, z.B.
isoelektrischer Punkt, Lektinbindungseigenschaften, Verhalten in der Ionenaustauscher-Chromatographie. CEA-
Präparationen, die sich auf Grand bipchemischer Kenngrößen voneinander unterscheiden lassen, sich bei Anwendung
immunchemischer Methoden jedoch identisch verhalten, werden als ,isomere Species6 oder Jsoantigene* bezeichnet.
Substanzen, die mit AntL-CEA Seren reagieren, jedoch nicht die für CEA gegebenen Kriterien erfüllen, werden als
,CEA-ähnliche Antigene' bezeichnet. CEA-ähnliche Antigene lassen sich weiter unterteilen in kreuzreagierende
Antigene, die CEArMembranvariante (CEA-M) sowie mehr oder weniger gut charakterisierte CEA-ähnliche Antigene,
die aus anderen Geweben als Colon-Carcinomen bzw. deren Leber-Metastasen isoliert wurden.
1) Prof. Dr. H. Breuer, member of the Editorial Board of our Journal, died August 20* 1982.
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Es ist noch nicht geklärt, ob CEA eher als ein Membranglycoprotein oder als ein sekretorisches Glycoprotein anzu-
sehen ist. Der Befund, daß auf der Membranvariante von CEA zusätzliche antigene Determinanten nachweisbar sind,
legt die Vermutung nahe, daß es sich um eine Vorstufe von CEA oder eine eigene CEA-Variante handelt. CEA-M
ist nur partiell in 0,6—0,9 mol/1 Perchlorsäure löslich.
Tumorzellen unterscheiden sich von den entsprechenden Normälzellen in Bezug auf Vorkommen u»4 Glycosylierurig
von Membranglycoproteinen. Möglicherweise ist die Glycosylierung von CEA oder CEA^ähnlichen. Antigenen organ-
oder phasenspezifisch. Durch die im Verlauf der CEA-Reinigung allgemein gebräuchliche Perchlorsäureextraktion
werden möglicherweise perchlorsäurelabile CEA-Varianten mit einer unvollständigen Glycosylierung der Kohlen-
hydratseitenketten nicht erfaßt.
Neuere Ergebnisse über die Isolierung von CEA-ähnlichen Antigenen aus anderen Geweben als Lebermetastasen yon
Coloncarcinomen sind widersprüchlich. Es wurden sowohl Antigene, die konventionellen CEA-Pfäparationen ähnlich
sind, als auch CEA-Varianten mit deutlichen Unterschieden in Molekulargewicht und Perchlorsäurelöslichkeit
beschrieben.
Introduction
Carcinoembryonic antigen (CEA)1 is the most exten-
sively studied human tumour marker. Since the first
description of CEA in 1965, it became evident that CEA
consists of a heterogenous population of isomeric species.
Furthermore, cross reacting antigens, membrane variants
and more or less organ specific CEA variants have been
described. The relationship between the different
members of the 'CEA family' has caused some confu-
sions.
In the following review, an attempt is made to give a pre-
liminary definition of CEA and CEA-related substances.
The biochemical properties of these substances are
discussed on the basis of recent findings on the bio-
synthesis of glycoproteins in normal and neoplastic
tissue.
Diagnostic Use and Limitations of the Determination of
CEA
Carcinoembryonic antigen of man was first described in
colonic carcinomas (l, 2) and first isolated frpm primary
colonic carcinomas and their liver metastases (3, 4, 5).
As a result of the introduction of radioimmunological
methods for the assay of CEA (6, 7, 8), the use and
limitations of CEA determinations for the diagnosis
of malignant tumours have become apparent. The
present stage of the application of the CEA determina-
tion for the diagnosis of cancer may be described äs
follows:
(a) High pretherapeutic CEA concentrations often in-
dicate a poor prognosis of the patient (9).
*) Abbreviations:
CEA = Carcinoembryonic antigen
NCA = normal cross reacting antigen
BGP-I = biliary glycoprotein I
CEA-M = membrane variant of CEA
GP-I = glycoprotein I
(b) The determination of CEA in serum before therapy
öf a malignant tumour and ät regulär intervals during
the further cpurse of the disease make it possible to
monitpr the theräpy and to detect tumpur recurfence
(i.e. local recurrence and/or distant metastases) earlier
than by other diagnostic means (10, 11, 12).
(c) CEA-producing primary tumours and their metastases
can be localized by immunöscintigraphy using radiö-
actively labeled CEA specific aiitibodies (13).
The determination of CEA did not fulfill the hopes for an
early and organ specific diagnosis of malignant tumours
for the following reasons:
— Early tumour stages are rarely accompanied by eleväted
CEA serum levels (10, 12, 14).
— CEA in serüm is also elevated in patients with varipus
non^malignant diseases (15).
— Attempts to isolate prgan-specißc pr tumoür-specific
CEA variants and to differentiate them from other
CEA variants in serum or other body fluids havß not
yet been successfül.
— According to the majority of the studies published,
CEA dpes not evoke a cellular or humoral immune
response in the autologöus organism (16, 17, 18).
— CEA determinations in serum or other body fluids are
not suitable for screening studies (19).
Possible Diagnostic and Therapeutic Applications ,öf
CEA in the Future
Certain questions may be formulated cpncerning future
research in the field of the clinical application of CEA:
(a) Is it possible to estäblish ä tumour or Organ specificity
of the CEA assay by the Isolation of CEA variants
from tissues of different prigin?
(b)JDoes a humoral or cellular immune response exist
against 'species-specific' or cryptantigenic determi-
nants on CEA or CEA related anfifeens (20)?
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(c) Is it possible to induce a humoral or cellular immune
response against autologous tumour tissue by
immunisation with chemicaJly modified CEA pre-
parations or CEA related substances?
(d)|Is it possible to make the chemotherapy of malignant
tumours more speeific by coupling chemotherapeutic
agents to CEA-specific antibodies?
Carcinoembryonic Antigen (CEA) and CEA-Related
Substances:
Definition and Classification
Despite intensive studies on the immunochemical and
biochemical characterization of CEA, it is still difficult
to give an exact definition of this glycoprotein. This
may be explained äs follows:
(a) CEA, like other glycoproteins, shows heterogeneity
with respect to various biochemical parameters.
(b) A number of cross reacting antigens share common
antigenic determinants with CEA.
(c) An antigen has been described which shows immuno-
logical identity with CEA when analysed by anti-CEA
sera. However, antisera which are induced against the
antigen itself react with additional determinants in
comparison with conventional CEA preparations.
Definition of the Carcinoembryonic antigen
The following definition of Carcinoembryonic antigen
takes into account the immunochemical properties, the
tissues in which the antigen has first been described and
from which it has been purified, the solubility in per-
chloric acid äs well äs some of the biochemical pro-
perties of the molecüle. In the first description (l, 2),
antisera directed against saline extracts from pöoled
primary colonic carcinomas and absorbed against saline
extracts from popled normal eo]pnic tissue were tested
against colonic carcinoma extracts by immunodiffusion,
immunpelectrophoresis and other immunolpgicäl
techniques. Using these methods, two 'tumour-
specific' and two 'tumpur-ässociated' antigens were
detected. Cpnsequentiy, the first papers of Gold and
co-workers refer tp 'carcinoembryonie antigens'.
During the first purification of CEA (3,4), the purifica-
tion procedure was inonitored by the antisera described
by Gold 8c Freedman (1,2). These antisera were not
monospecific. The purification prpcedure described by
Krupey et ai. (3,4) involved the extraction of the tissue
homogenate in 0.6 mol/1 perchloric acid, a paper-block
electrophoresis, and a gel chromatography on Sephadex-
G-200. According toColigan et al. (5), the electrpphor-
etic purification Step may be omitted since it has no
significant effect. Therefore, it may be concluded that
the antigens described in the first publications ofGold
& Freedman (l, 2): were separated from each other due to
differences in either molecular weight or perchloric acid
solubility. Probably, both assumptions are correct.
(1) The perchloric acid soluble cross reacting antigen
NCA (normal cross reacting antigen (21)) which, äs
CEA, is present in colonic carcinomas in high concen-
trations and which shows the same electrophoretic
mobility äs CEA, can be separated from CEA by gel
filtration.
(2) According to recent studies a further CEA-related
antigen may be extracted from colonic carcinoma
tissue by the use of water, saline or detergents (20,
22—25). The antigen does not seem to be identical
with the known cross reacting antigens äs it is less
soluble in perchloric acid (20, 22—25) and it exhibits
a molecular weight in the ränge of conventional CEA
preparations (200000 daltons (22, 25)). The purity of
CEA preparations is checked by immunochemical and
biochemical methods. In immunelectrophoresis, puri-
fied CEA gives a single precipitation line against anti-
sera which have been induced with crude perchloric
acid extracts from colonic carcinomas. Analytical ultra-
centrifugation reveals a single peak in purified CEA
preparations (3,4).
The perchloric acid solubility of CEA is due to its high
carbohydrate content (26, 27). The oligosaccharide
side chains are liriked to the peptide by an alkali-stable
N-glycosidic bond between N-acetylghicosamine and
asparagine (26, 27).
Some criteria which must be fulfilled if a glycoprotein is
to be designated äs Carcinoembryonic antigen (CEA)
are listed below:
(a) reaction with antisera directed against saline extracts
of popled primary colonic carcinomas and absorbed
with saline extracts of pöoled normal colon using the
methods described by Gold & Freedman (1).
(b) solubility in 0.6—1.0 mol/1 perchloric acid.
(c) N-glycosidic linkage pf the oligosaccharide side
chains to asparagine.
(d)molecular weight of 180000-200000 daltons.
(e) single precipitation line in the ß-globulin ränge in
immunoelectrophoresis using antisera against crude
0.6—1.0 mol/1 perchloric acid extracts from primary
colonic carcinomas or liver metastases from primary
colonic carcinomas, depending on the source of the
CEA-preparation.
(f) single boundary in the analytical ultracentrifuge.
Generally, the biochemical properties of CEA refer to
CEA preparations from liver metastases of colonic or
rectal carcinomas (for reviews see I.e. (28,29)). The
amino acid composition äs well äs the sequence of the
31 N-terminal amino acids of CEA preparations from
liver metastases of different individuals are remarkably
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stable (28, 30). This is not true for the carbohydrate
composition (28). The differences in the carbohydrate
composition of different CEA preparations are probably
the main reason for tlie heterogeneic behaviour of
different CEA preparations in isoelectric focussing (31),
ion exchange chromatography (32) and lectin binding
(33,34). According to Gottsehalk (see 35), biochemical
heterogeneity of glycoproteins implies statistically
significant differences between the distributions of the
respective biochemical parameters. In this context, it
should be mentioned that according to some investigators,
the carbohydrate moiety of CEA may be altered by
treatment with perchloric acid (24).
CEA preparations that show statistically significant differ-
ences with respect to biochemical parameters but behave
identically when immunochemical methods are applied,
are called 'isomeric species' (e.g. CEA-S (36)) or 'iso-
antigens' (37).
CEA-related antigens
In the following, antigens which react with anti-CEA
sera but do not fulfill the criteria given for CEA, are
designated 'CEA related antigens'.
Cross reacting antigens
Cross reacting antigens show a pattern of partial im-
munochemical identity with CEA in double diffusion
or equilibrium radioimmunoassays when non-absorbed
anti-CEA sera are used. Cross reacting antigens may
reveal antigenic determinants which are not present
in CEA (e.g. NCA1) (21), BGP-I1) (38)). In this con-
text it should be mentioned that the specificity of
the antisera which have been induced against the same
immunogen in different animals of the same or different
species may differ considerably (39). Furthermore, the
reactivity of an antiserum in immunodiffusion may be
different from that in radioimmunoassay (40, 41). For
recent reviews on immunochemical and biochemical
properties of cross reacting antigens see (42,43).
Membrane variant ofCEA (CEA-M)
Leung et al. (20) isolated a glycoprotein from crude
membrane fractions of liver metästases of colonic
carcinomas using sodium dodecyl sulfate (SDS). In
immunodiffusion and radioimmunoassay, the antigen
behaved qualitatively äs CEA when anti-CEA sera were
applied. However, antisera which were induced against
the membrane variant reacted with antigenic determi-
nants which were not present in cönventional CEA
preparations. The membrane variant is only partially
soluble in 0.6 mol/1 perchloric acid. For these reasons,
the membrane antigen is a distinct CEA related antigen
which, according to the defmition given above, differs
from the cross reacting antigens. The membrane antigen
has been designated 'CEA-M'. The molecular weight of
CEA-M is similar to that of CEA. Prelimiiiary results
indicate that antisera against peptides resulting from the
chemical cleavage of CEA-M seem promising for the
develppment of a specific radioimmunoassay for
gästrointestinal tumours (23). '
CEA and CEA-related substances in wäter or saline
extracts ofprimary colonic carcinomas and/or their Hver
metästases
Different investigators have demonstrated twö precipita-
tion lines in immunodiffusion when water or saline
extracts from priinary colonic carcinomas and/or their
liver metästases are tested against different antisera;
these antisera were raised against the following different
CEA or CEA-related antigen preparations:
(a) a fraction froin a cönventional CEA preparation with
a low affinity to concanavalin-A (24, 34).
(b) a preparation, pärtially purified from saline extracts
o£ liver metästases of colonic carcinomas by Sephärose
4B and Sephadex G200 gel filtratipn, with a low
affinity to concanavalin-A (mpnitoring of CEA posi-
tive fractions by a CEA specific radioimmunoassay
(25)).
(c) a preparation partially purified from an ulträsofiicated
homogenate of a liver metastasis öf a colonic carci-
noma by ion exchange, concariavälift-A, Sepharpse
4B and Sephadex G200 chromatography (monitoring
of the CEA positive fractions by a CEA specific radio-
immunoassay (22)).
The identity of the antigens described by the different
investigators has not yetfoeen estaWished.
The antigen in the second precipitatipn line does not
seem to be identical with the known cross reacting
antigens, äs it is only partially soluble in perchloric acid
(22-25) and the molecular weight is about 200000
daltons (25). Furthermore, pne of the antisera described
was extensively absorbed by extracts from normal
colonic mucosa, liver and spieen (34).
It cannot be excluded that the second precipitation line
described above is due to an artefact, resulting from
dimerizätiori Pr polymerization of the antigens, which
may lead to a masking of some of the antigenic deter-
minants (44). Alternatively, one of the two antigens
may be identical with CEA-M (20). However, the
second precipitation line may also be related to a
distinct CEA variant different from the CEA-related
antigens mentioned so far.
CEA-related substances in carcinomas other than
colorectal cancer
Recent investigations indicate that CEA-related sub-
stances isolated from mammary carcugiomas differ from
colorectal CEA preparations both immunochemically
J. Clin. Chem. Clin. Biochem. / Vol. 20,1982 / No. 10
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and biochemically. To date, the results regarding bio-
chemical properties, e.g. molecular weight, äs well äs
immunochemical properties are contradictory (45-47).
Purified CEA related antigens from the cyst fluid from
cystadenocarcinomas of the ovary exhibit the same
molecular weight äs CEA;however, only about 10%
of a given preparation is soluble in perchloric acid (48).
These results are in contradiction to the studies of
Chism et al. (46) who described perchloric acid-
soluble antigens in both cystadenocarcinomas of the
ovary and mammary carcinomas with a molecular weight
significantly lower than that of CEA. The molecular
weight of CEA-related substances which were isolated
from culture fluids of prostatic cancer cells was signif-
icantly higher than the molecular weight of conventional
CEA preparations (49). CEA preparations from carcino-
mas of the bladder showed great similarities to CEA
preparations from colonic carcinomas (50).
Degradation products
It cannot be excluded that due to intratumoural pro-
teoly tic cleavage or due to cleavage during the Isolation
procedure, cryptantigenic determinants are exposed
in the degradation products of CEA. These degradation
products may mimic CEA-related antigens with their
own distinct antigenic determinants (51, 52).
CEA and CEA-Related Antigens:
Biochemical Considerations
In the following, the biochemical and inununochemical
prqperties of CEA and CEA-related antigens are discussed
in the context of the biosynthesis of glycoproteins in
nonnal and neoplastic tissües.
Is CEA a membrane-bound ör a secretory
glycoprotem?
Imrnunohistochemicäl investigations using light micros-
copy showed that in colorectal carcinomas, CEA is
localized in the apical cell membranes of the tumour
cells bordering the gländülar lumina (53, 54). According
tp electron microscopic studies, CEA is a component
of the glycocälyx (55). The findSng that in colonic
carcinoma cells, CEA exhibits a marked cytöplasmic
localization similar to secretory glycoproteins (56),
has not been confirmed. According to our results,
a cytöplasmic localization of CEA is found in crypt
cells which are adjacent to carcinomas äs well äs in
ulcerative colitis specimens (57). In specimens of linitis
plastica, signet ring cells show ä marked cytöplasmic
localization of CEA (54). In medullary carcinomas of
the thyroid gland, CEA is a component of the eell
membranes bordering the lumina of the tumour
glands, äs well äs a typical secretion product, showing
an iritracytoplasmic and pericellular localization (58).
CEA or CEA-related antigens are present in various body
fluids (e.g. cyst fluid of mammary cysts (59); urine (60))
and in normal colon washings (61). According to our
investigations, membrane-bound CEA seems to be rele-
ased into the blood stream from necrotic colonic carci-
noma tissue (14). GP-I1) (62), which is similar to or
identical with CEA, is tightly bound in the cell
membranes of cultivated colonic carcinoma cells. The
same finding applies to CEA-M (20, 23).
Biosynthesis of glycoproteins with an alkali-
stable linkage of the carbohydrate side chains
to asparagine
CEA belongs to the class of glycoproteins in which the
carbohydrate side chains are linked to asparagine via
N-acetylghicosamine (26, 27). The N-glycosidic bond
is stable against mild alkali. In recent years, important
progress towards the understanding of the biosynthesis
of this class of glycoproteins has been made.
The biosynthesis of the oligosaccharide side chains
begins with the formation of oligosaccharide-
dolicholphosphate. This oligosaccharide-lipid molecule
contains the so-called 'core' oligosaccharides of the
glycoprotein. During the synthesis of the peptide chain,
the oligosaccharide unit is transferred to asparagine
when an Asn-X-Ser/Thr-tripeptide sequence has been
translated and is oriented so that it can interact with
both the Substrate oÜgosaccharide-P-P-dolichol and
the membrane associated oligosaccharide transferase
(63,44). Before the glycosylation of the glycoprotein
is continued, additional glucosyl and mannosyl residues
are clipped (65, 66). Both membrane and secretory
glycoproteins seem to be closely associated to the
membrane of the rough endoplasmic reticulum äs long
äs the oligosaccharides are transferred from the oligo-
saccharide-^lipid to tiie peptide (64). When the synthesis
. of the peptide chain and the assembly of the oligo-
saccharide chains are terminated, glycosylation of the
'eorriplex' glycoproteins continues in the Golgi appa-
ratus (67). Whereas membrane glycoproteins remain
mejnbrane-bound during the whole process of glyco-
sylation due to a hydrophobic sequence near the
C-terminal end of the peptide chain, secretory pro-
teins remain membrane-associated only until translation
is terminated (64).
Many of the results cited above suggest that CEA and
CEA-related antigens show characteristics of membrane-
bound äs well äs secretory glycoproteins. If this assump-
tion is correct, there should be differences in the structure
and antigenicity of secretory and membrane-bound CEA
variants. The results ofLeung et al. (20) point in this
direetion.
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G'lycosylation of membrane glycoproteins in
tumour cells compared to the corresponding
normal cells
Studies on differences between normal and malignant
cells regarding the occurrence and structure of
membrane glycoproteins are contradictory. Some
investigators found a higher percentage of sialo-
glycopeptides in the membrane fractions of trans-
formed cells äs compared with the corresponding
normal cells (68-70). Other investigators föund an
incomplete glycosylation of membrane-boünd glyco-
proteins in tumour cells (71—73). It has been suggested
that the cell membranes of foetal and tumour cells are
characterized by an incomplete glycosylation of glyco-
proteins accompanied by the exposure of galäctosyl
transferases on the cell membranes (74—76). Kim et .
found a lower content of carbohydrates in the membrane
glycoproteins of colonic adenocarcinpmas äs compared
with normal colonic mucosa. The content of galactps-
amine, fucose and sialic acid was significantly reduced (77).
··. \
Considering the investigations cited above, it seems
possible that a different degree of glycosylation may
be found in CEA from normal and neoplastic tissue.
This hypothesis is supported by the findings ofRogers
et al. (78) who described differences in the lectin
binding of CEA preparations from normal colon and
from colonic carcinpmas.
Organ and phase specificity of the biosynthesis
of glycoproteins
The carbohydrate composition of glycoproteins is not
directly controlled by the base sequence of the DNA.
However, this does not imply that the so-called miero-
heterogeneity of glycoproteins, which is due to differ-
ences in the carbohydrate composition, is random. It
has been shown that the npnrandom attachment of
various terminal sugars in the complex-type oligo*
saccharides may be related to the fact that the glycosyl-
transferases responsible for the addition of the respective
sugars have specificity requirements that go beyond the
acceptor sugar residue to encompass other structural
features on the oligosaccharide (79, 80).
The concanavalin-A binding of -foetpprotein produced
in the yolk sac is different frpm that of liver a-foeto-
protein (81). CEA-related antigens from cancer of the
breast and ovary showed a lower binding to concan-
avalin-A than the corresponding CEA related antigens in
colorectal carcinomas (46). Accordüig to Rute and co-
workers, the biochemical heterogeneity of CEA is due
to a phase specificity of gene expression (82).
Conclusion
Carcinoembryonic antigen (CEA) is mainly defined by its
immunochemical properties. Essential biochemical
characteristics of CEA are its molecular weight of
180000-200000 dältöns, the N-glycosidic linkage of the
oligosaccharide units between N-acetylglucosamine and
asparagine, and its solubility in 0.6—1.0 mol/1 perchloric
acid. The amino acid composition and, äs far äs analysed,
the sequence of the 24 N-terminal anifho acids are remark-
ably stable in liver metastases of colonic carcinomas
from different individuals äs well äs in normal colon
washings (28). CEA is composed of a single polypeptide
chain. These findings lead tö the assumption that the
amino acid sequence of CEA is determined by ä single
gene which shows great stability in different individuals
äs well äs in normal and neoplastic colonic tissues.
contrast, the carbohydrate composition öf differeiit
CEA preparations is heterpgenous. On the omo hand,
this may be due to a partial degf adätion of the oligo-
saccharide side chains during tumour necrosis, On the
other hand, this heterogeneity may be tf aced back to a
phase or organ specificity in the biosynthesis of the
carbohydrate moiety of CEA.
In water and saline extracts äs well äs in the inembräne
fraction of colonic carcinomas and/or their liver meta-
stases, a CEA-related perchloric acid lable antigen is
present, providing the ppssibility Pf an artefact due to
aggregation phenpmenä is exöluded. This CEA-related
antigen may be either a CEA precursor or a membraiie
variant different from CEA. 'nie partial perchloric acid
insolubility of the variant may be due to. the membf ane
associated part of the molecule and/ör to an incomplete
glycosylation. When an antiserum is induced against the
variant some äntibody populations may possibly be
directed against the membrane-associated portiön of the
moleeule. ^
One might speculate that during tumour progression
antigenic determinants of membf ane-bound CEA
variants which are normäffly covefed in the cell membrane
becpme exposed thus stimulating the autölogous
immune System.
The cross reacting antigens differ from CEA in their
amino acid composition and, äs far äs analysed, in tiie
sequence of the 24 N-tenninal amiiio äcids (20). CEA
and NCA1) are present in the same eells of colonic
carcinomas (54). Therefpre, the synthesis of CEA and
NCA1) is probably coded by different genes,
The available datä regärding the Isolation and characteri-
zatiön of CEA-related substances from npn-colonic carei-
nomas are contradictory. The high molectilär weight of
the prostatic CEA variant suggests a genetically deter-
mined difference pf the protein moiety in>comparispn
with colöirectäl CEA preparations. the low perchloric
acid solubility of the ÖEA variant present iia the cyst
fluid of cystadenpcaircinomas of the öväry may indicate
an organ-specific biosynthesis of the oligosaccharide
side chains. ^ ?
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In recent years, many efforts have been made to improve
the organ and tumour specificity of the CEA determi-
nation. This aim has not been achieved äs yet. However,
some of the findings discussed here indicate that progress
may be possible by the isolation and characterization of
CEA and CEA-related antigens from different cell frac-
tions'of tumours of different origin, using methods
that avoid the harsh perchloric acid extraction of the
tissue.
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